CLAIMS

WHAT IS CLAIMED IS:

1. An antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like ligand 1A (TL1A), comprising: (a) a heavy chain variable region comprising SEQ ID NO: 104 and (b) a light chain variable region comprising SEQ ID NO: 201.
2. The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment thereof is a humanized antibody or humanized antigen binding fragment.
3. The antibody or antigen binding fragment of claim 1 or 2, wherein the antibody or antigen binding fragment comprises a human IgG1 heavy chain constant region.
4. The antibody or antigen binding fragment of any one of claims 1 to 3, wherein the antibody or antigen binding fragment comprises a human kappa light chain constant region.
5. The antibody or antigen binding fragment of claim 3, wherein the heavy chain constant region comprises one amino acid deletion.
6. The antibody of claim 1, wherein the antibody comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 505 and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 514.
7. The antibody of claim 6, wherein a heavy chain constant region of the heavy chain comprises one amino acid deletion.
8. An isolated polynucleotide encoding the antibody or antigen binding fragment of any one of claims 1-7.
9. An isolated vector comprising the polynucleotide of claim 8.
10. A host cell comprising the vector of claim 9.
11. A method of making an antibody or antigen binding fragment thereof that binds to TL1A, wherein the method comprises:
    a) culturing the host cell of claim 10 under conditions suitable for expression of the polynucleotide encoding the antibody or antigen binding fragment thereof; and
    b) isolating the antibody or antigen binding fragment thereof.
12. A pharmaceutical composition for use in the treatment of inflammatory bowel disease (IBD) in a subject in need thereof, wherein the pharmaceutical composition comprises a therapeutically effective amount of the antibody or antigen binding fragment of any one of claims 1-7.

13. Use of a therapeutically effective amount of the antibody or antigen binding fragment of any one of claims 1-7 in the manufacture of a medicament for the treatment of inflammatory bowel disease (IBD) in a subject in need thereof.
14. The use of claim 13, wherein the IBD is Crohn’s disease.
15. The use of claim 13, wherein the IBD is ulcerative colitis.